生物标志物：干燥综合征的新型生物标志物——是时候治疗患者了。 - Suppr

Biomarkers: new biomarker for Sjögren's syndrome--time to treat patients.

作者信息

Kroese Frans G M, Bootsma Hendrika

机构信息

Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, AA21, PO Box 30001, 9700 RB Groningen, Netherlands.

出版信息

Nat Rev Rheumatol. 2013 Oct;9(10):570-2. doi: 10.1038/nrrheum.2013.143. Epub 2013 Sep 17.

DOI:10.1038/nrrheum.2013.143

PMID:24045708

Abstract

摘要

相似文献

Biomarkers: new biomarker for Sjögren's syndrome--time to treat patients.生物标志物：干燥综合征的新型生物标志物——是时候治疗患者了。

Nat Rev Rheumatol. 2013 Oct;9(10):570-2. doi: 10.1038/nrrheum.2013.143. Epub 2013 Sep 17.

Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF.利妥昔单抗治疗原发性干燥综合征患者时局灶性淋巴细胞性涎腺炎的持续存在：腺源性BAFF的可能作用

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1123-1124. Epub 2016 Aug 2.

The uncertain role of immunosuppressive agents in Sjögren's syndrome.免疫抑制剂在干燥综合征中的不确定作用。

Cleve Clin J Med. 1997 Nov-Dec;64(10):523-6. doi: 10.3949/ccjm.64.10.523.

Management of patients presenting with Sjogren's syndrome.干燥综合征患者的管理

Best Pract Res Clin Rheumatol. 2006 Aug;20(4):791-807. doi: 10.1016/j.berh.2006.05.003.

Treatment with infliximab restores normal aquaporin 5 distribution in minor salivary glands of patients with Sjögren's syndrome.英夫利昔单抗治疗可恢复干燥综合征患者小唾液腺中正常水通道蛋白5的分布。

Arthritis Rheum. 2002 Aug;46(8):2249-51. doi: 10.1002/art.10440.

Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.贝丽珠单抗治疗原发性干燥综合征 12 个月的疗效和安全性：BELISS 开放性 II 期研究。

Rheumatology (Oxford). 2015 Dec;54(12):2249-56. doi: 10.1093/rheumatology/kev257. Epub 2015 Aug 4.

[Sjögren's syndrome].[干燥综合征]

Z Rheumatol. 2010 Feb;69(1):9-10. doi: 10.1007/s00393-009-0597-1.

Eosinophilic gastrointestinal disorder preceding Sjögren's syndrome.干燥综合征之前的嗜酸性粒细胞性胃肠道疾病。

Joint Bone Spine. 2017 Jan;84(1):109-110. doi: 10.1016/j.jbspin.2015.12.008. Epub 2016 Apr 27.

Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.原发性干燥综合征活动期严重的健康相关生活质量损害及患者报告结局：来自一项大型治疗试验的数据

Arthritis Care Res (Hoboken). 2017 Apr;69(4):528-535. doi: 10.1002/acr.22974.

Efficacy of tacrolimus in Sjögren's syndrome-associated CNS disease with aquaporin-4 autoantibodies.

J Neurol. 2009 Oct;256(10):1762-4. doi: 10.1007/s00415-009-5175-6. Epub 2009 May 26.

引用本文的文献

Tear cathepsin S as a candidate biomarker for Sjögren's syndrome.泪液组织蛋白酶 S 作为干燥综合征的候选生物标志物。

Arthritis Rheumatol. 2014 Jul;66(7):1872-81. doi: 10.1002/art.38633.

本文引用的文献

EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.欧洲抗风湿病联盟干燥综合征疾病活动指数（ESSDAI）在一项随机对照试验中对显示利妥昔单抗治疗的疗效很敏感。

Ann Rheum Dis. 2014 Feb;73(2):472-4. doi: 10.1136/annrheumdis-2013-203736. Epub 2013 Aug 12.

Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.在原发性干燥综合征患者中，B细胞清除疗法后主要促炎细胞因子减少。

Ann Rheum Dis. 2013 Dec;72(12):2048-50. doi: 10.1136/annrheumdis-2013-203447. Epub 2013 Jul 17.

MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome.MxA 作为一种临床应用的生物标志物，可用于鉴定原发性干燥综合征中的系统性 I 型干扰素。

Ann Rheum Dis. 2014 Jun;73(6):1052-9. doi: 10.1136/annrheumdis-2012-202552. Epub 2013 Jul 6.

The interferon signature in autoimmune diseases.自身免疫性疾病中的干扰素特征。

Curr Opin Rheumatol. 2013 Mar;25(2):248-53. doi: 10.1097/BOR.0b013e32835c7e32.

Topical and systemic medications for the treatment of primary Sjögren's syndrome.原发性干燥综合征的局部和全身药物治疗。

Nat Rev Rheumatol. 2012 May 1;8(7):399-411. doi: 10.1038/nrrheum.2012.53.

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.类风湿关节炎患者对利妥昔单抗无反应的干扰素 I 型特征预测。

Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi: 10.1186/ar3819.

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.EULAR 干燥综合征患者报告指数（ESSPRI）：原发性干燥综合征共识患者指数的制定。

Ann Rheum Dis. 2011 Jun;70(6):968-72. doi: 10.1136/ard.2010.143743. Epub 2011 Feb 22.

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.EULAR 干燥综合征疾病活动指数：原发性干燥综合征共识系统性疾病活动指数的制定。

Ann Rheum Dis. 2010 Jun;69(6):1103-9. doi: 10.1136/ard.2009.110619. Epub 2009 Jun 28.

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome.原发性干燥综合征靶器官中干扰素通路的激活及浆细胞样树突状细胞募集

Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2770-5. doi: 10.1073/pnas.0510837103. Epub 2006 Feb 13.

Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects.小唾液腺的基因表达谱分析能明确区分原发性干燥综合征患者与健康对照者。

Arthritis Rheum. 2005 May;52(5):1534-44. doi: 10.1002/art.21006.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Biomarkers: new biomarker for Sjögren's syndrome--time to treat patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献